Thu Sep 26 13:00:14 UTC 2024: ## 23andMe Faces Uncertain Future as Directors Resign Amid Takeover Bid

**SAN FRANCISCO** – The future of genetic testing giant 23andMe hangs in the balance as directors have resigned from the company’s board after CEO Anne Wojcicki’s attempt to take the company private fell through.

Wojcicki, who has been pushing for a private acquisition since April, offered $0.40 per share for outstanding shares in July. However, the board’s special committee rejected the proposal, deeming it inadequate and not in the best interests of shareholders.

The directors, in a letter to Wojcicki, stated they had not received a “fully financed, fully diligenced, actionable proposal” that met their criteria. They have also ruled out further extensions, effectively ending the takeover bid.

This decision comes at a critical time for 23andMe, which has been grappling with declining stock prices and financial troubles. The company’s stock price has plummeted by 96% since its peak in 2021, falling below the $1 threshold required by the Nasdaq. This has triggered a notice of potential delisting, giving the company three months to recover or face removal from the exchange.

Adding to the company’s woes is a $30 million fine and security monitoring requirements imposed for a 2023 data breach that exposed the personal information of 6.9 million customers.

Despite its initial success, 23andMe has never turned a profit and reported a 27% revenue decline in fiscal 2024.

While Wojcicki remains confident in 23andMe’s long-term potential in genetic sequencing and drug discovery, the company faces an uphill battle to regain its footing. The success of its strategic partnerships with pharmaceutical giants like GSK, who are using the company’s database for drug discovery, will be crucial.

The immediate future of 23andMe remains uncertain. While Wojcicki plans to assemble a new board and explore further partnerships, the question remains whether investors are willing to wait for the company to deliver on its long-term vision in a rapidly evolving market.

Read More